Spectrum Pharma (SPPI) fails to win FDA panel backing
- Techs buoy S&P, Nasdaq; Goldman pushes Dow to record high
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Oil hits 16-month high in buying rush after OPEC agreement
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Berkshire Hathaway (BRK-A) Book Value Could Be Boosted by $29B from Trump Tax Plan - Analyst
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Spectrum Pharma (NASDAQ: SPPI) fails to win FDA panel backing
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
- Sears Holdings Corp (SHLD) volatility elevated into Q3 and outlook
- Options expected to have Increasing volume
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!